Clinical Trial Update: Evaluating the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination With Optimized Multidrug Background Regimen (OBR) for Multidrug-Resistant Tuberculosis (MDR-TB) in HIV-Infected and HIV-Uninfected Children With MDR-TB [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update confirms completion of Phase 1/2 studies evaluating the pharmacokinetics, safety, and tolerability of delamanid in combination with an opt…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection
• Tuberculosis

Drugs mentioned

• Delamanid (delamanid)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Tuberculosis, HIV Infections | Phase 1, Phase 2 | Status: COMPLETED